A phase II randomised, double blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of CT327 topical ointment (0.05% and 0.5% w/w) compared to vehicle, in subjects with mild or moderate atopic dermatitis with at least moderate pruritus

Trial Profile

A phase II randomised, double blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of CT327 topical ointment (0.05% and 0.5% w/w) compared to vehicle, in subjects with mild or moderate atopic dermatitis with at least moderate pruritus

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs SNA 120 (Primary)
  • Indications Atopic dermatitis; Pruritus
  • Focus Therapeutic Use
  • Sponsors Creabilis SA
  • Most Recent Events

    • 19 Mar 2015 Results published in Acta Dermato-Venereologica, according to a Creabilis media release.
    • 17 Oct 2013 New trial record
    • 18 Sep 2013 The first patients have been treated, according to a Creabilis SA media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top